Inversago Pharma is a privately-owned, clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists. In 2022, the Company completed a Series C funding of $95 million CAD (approximately $70 million USD), led by New Enterprise Associates (“NEA”).

Additional new investors Forbion’s Growth Opportunities Fund and Amgen Ventures joined current investors including Forbion’s Ventures Fund IV, Fonds de solidarité FTQ, Genesys Capital, AmorChem, JDRF T1D Fund and adMare BioInnovations in the financing round.

Proceeds from the Series C financing will be used to move Inversago’s lead program, INV-202, into a Phase 2 clinic trial in Diabetic Kidney Disease in Q4 2022 and develop other key preclinical programs.

In 2020, the Company had secured a $35 million USD Series B financing led by Forbion from the Netherlands, with important participation by Fonds de solidarité FTQ and existing investors Genesys Capital, JDRF T1D Fund, AmorChem, Anges Québec Capital, adMare BioInnovations, and other angels.


About NEA
New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With nearly $24 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm’s track record of investing includes more than 260 portfolio company IPOs and more than 440 mergers and acquisitions.


About Forbion
Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages well over EUR 2 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of over 30 life sciences investment professionals that have built an impressive performance track record since the late nineties with investments in 92 companies. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. The firm is a signatory to the United Nations Principles for Responsible Investment. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.

About Fonds de solidarité FTQ
The Fonds de solidarité FTQ invests to build a better society by channeling the savings of its 748,371 shareholders into development and risk capital investments to help Québec transition to a green economy, a people-centred world of work, and a healthier society. The Fonds offers businesses unsecured financing and strategic support. With $17.4 billion in net assets as of May 31, 2022, the Fonds has supported 3,620 partner companies and 296,927 jobs.

About Genesys Capital
Genesys Capital is one of the largest Canadian-based venture capital firms exclusively focused on the life sciences industry. Genesys is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys Capital accelerates the development of commercially viable emerging companies that represent disruptive life sciences investment opportunities.

About Amgen Ventures
Amgen Ventures is Amgen’s corporate venture capital fund, dedicated to investing in emerging companies and technologies to advance promising new medicines and solutions to healthcare’s biggest challenges. More about Amgen Ventures

About the JDRF T1D Fund
Launched in December 2016 and now with $175 million in assets under management, the JDRF T1D Fund is the first scale, mission-driven venture philanthropy fund accelerating life-changing solutions and acting as a catalyst for scale commercial investments to cure, prevent, and treat type1 diabetes (T1D). Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the capital and focus necessary to advance drugs, diagnostics, and devices into the hands of those living with T1D.

About AmorChem
AmorChem is a leading early-stage venture capital fund launched in 2011 in Montreal. The AmorChem team utilizes its deep understanding of fundamental science to uncover its therapeutic potential and focuses its core expertise in translational research to accelerate therapeutic drug discovery and development across a broad spectrum of disease areas. The fund capitalises on both its venture capital expertise and its entrepreneurial experience to spark the creation of start-up companies and help shape them into the next generation of biotech companies. With over $85M under management, AmorChem has financed over 30 university projects and started up several biotechnology companies from the fruits of this innovative research.

About AQC Capital
AQC Capital is a venture capital fund with more than $ 150M under management available to innovative start-ups in Quebec. Always investing with successful angels who are members of the Anges Québec Network, the AQC Capital team offers active and dynamic support in addition to the capital necessary for entrepreneurs to elevate themselves to the highest heights. To date, AQC Capital has invested in 53 innovative companies.

About adMare BioInnovations
With a wealth of globally-competitive scientific discovery, Canada is primed to lead the life sciences world. To make this a reality, at adMare BioInnovations, we use our scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build strong life sciences companies, robust ecosystems and industry-ready talent — and re-invest our returns back into the Canadian industry to ensure it is sustained for the long-term. As part of our commitment to build talent, we have created the adMare Academy, dedicated to providing the specialized training required to foster the next generation of highly qualified personnel who will drive the growth of Canadian life science companies.


For more information on investment opportunities, please contact us:


Inversago Pharma benefits from the financial support of the Ministère de l’Économie et de l’Innovation du Québec